Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (35)
Patrick Gould, Tasnim Salam, Laura Kimberly, Alison Bateman-House & Holly Fernandez Lynch. (2022) Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs. JAMA Network Open 5:11, pages e2239766.
Crossref
Crossref
Jeremiah Stout, Cambray Smith, Jan Buckner, Alex A. Adjei, Mark Wentworth, Jon C. Tilburt & Zubin Master. (2021) Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center. PLOS ONE 16:12, pages e0261478.
Crossref
Crossref
Stefan F. Vermeulen, Marjolijn Hordijk, Nikkie Aarts & Eline M. Bunnik. (2021) Factors of feasibility: an interview study of physicians’ experiences of expanded access to investigational drugs in three countries. Humanities and Social Sciences Communications 8:1.
Crossref
Crossref
Jan Borysowski, Anna C. F. Lewis & Andrzej Górski. (2021) Conflicts of interest in oncology expanded access studies. International Journal of Cancer 149:10, pages 1809-1816.
Crossref
Crossref
Jan Borysowski & Andrzej Górski. (2021) ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study. Journal of Medical Internet Research 23:10, pages e26890.
Crossref
Crossref
SUMEL ASHIQUE & TAHAMINA KHATUN. (2021) COMPASSIONATE USE OF INVESTIGATIONAL DRUG DURING EMERGENCY CONDITIONS AND ASSOCIATED ETHICAL ASPECTS, CHALLENGES, AND BENEFITS. Asian Journal of Pharmaceutical and Clinical Research, pages 5-12.
Crossref
Crossref
J Harvey Turner. (2021) Ethics of Pharma Clinical Trials in the Era of Precision Oncology. Cancer Biotherapy and Radiopharmaceuticals 36:1, pages 1-9.
Crossref
Crossref
Jan Borysowski & Andrzej Górski. (2020) Ethics framework for treatment use of investigational drugs. BMC Medical Ethics 21:1.
Crossref
Crossref
Michael Buckley & Collin O’neil. (2020) The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs. The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine 45:2, pages 193-211.
Crossref
Crossref
YashashriC Shetty, Smita Brahma & PS Manjesh. (2020) Compassionate drug use: Current status in India. Perspectives in Clinical Research 11:1, pages 3.
Crossref
Crossref
Eline M. Bunnik & Nikkie Aarts. (2019) What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. BMC Medical Ethics 20:1.
Crossref
Crossref
Jan Borysowski & Andrzej Górski. (2019) Compassionate use of unauthorized drugs: Legal regulations and ethical challenges. European Journal of Internal Medicine 65, pages 12-16.
Crossref
Crossref
Marjorie A. Speers. (2019) Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. Pharmaceutical Medicine 33:2, pages 89-98.
Crossref
Crossref
Scott Moerdler, Lindy Zhang, Elena Gerasimov, Chong Zhu, Tamar Wolinsky, Michael Roth, Nancy Goodman & Daniel A. Weiser. (2019) Physician perspectives on compassionate use in pediatric oncology. Pediatric Blood & Cancer 66:3, pages e27545.
Crossref
Crossref
Kelly Folkers, Carolyn Chapman & Barbara Redman. (2019) Federal Right to Try: Where Is It Going?. Hastings Center Report 49:2, pages 26-36.
Crossref
Crossref
Jan Borysowski & Andrzej Górski. 2019. Phage Therapy: A Practical Approach. Phage Therapy: A Practical Approach
379
385
.
David J. Cote. 2019. Ethics of Innovation in Neurosurgery. Ethics of Innovation in Neurosurgery
93
103
.
Carolyn P. Neuhaus & Rachel L. Zacharias. (2018) Compassionate use of gene therapies in pediatrics: An ethical analysis. Seminars in Perinatology 42:8, pages 508-514.
Crossref
Crossref
Brandon Brown, Camerin Ortiz & Karine Dubé. (2018) Assessment of the Right-to-Try Law: The Pros and the Cons. Journal of Nuclear Medicine 59:10, pages 1492-1493.
Crossref
Crossref
Eline M. Bunnik, Nikkie Aarts & Suzanne van de Vathorst. (2018) Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs. Health Policy 122:9, pages 977-983.
Crossref
Crossref
Margaret F. Riley. (2021)
A RAT by Another Name: 21
st
Century Cures Act and Stem Cell Therapies
. American Journal of Law & Medicine 44:2-3, pages 291-308.
Crossref
Crossref
D. Carrieri, F.A. Peccatori & G. Boniolo. (2018) The ethical plausibility of the ‘Right To Try’ laws. Critical Reviews in Oncology/Hematology 122, pages 64-71.
Crossref
Crossref
Jan Borysowski, Hans-Jörg Ehni & Andrzej Górski. (2017) Ethics review in compassionate use. BMC Medicine 15:1.
Crossref
Crossref
Tamra Lysaght. (2017) Accelerating regenerative medicine: the Japanese experiment in ethics and regulation. Regenerative Medicine 12:6, pages 657-668.
Crossref
Crossref
Denise Meyerson. (2017) Medical Negligence Determinations, the “Right to Try,” and Expanded Access to Innovative Treatments. Journal of Bioethical Inquiry 14:3, pages 385-400.
Crossref
Crossref
Laura L. Kimberly, Marc M. Beuttler, Michael Shen, Arthur L. Caplan & Alison Bateman-House. (2017) Pre-approval Access Terminology: A Cause for Confusion and a Danger to Patients. Therapeutic Innovation & Regulatory Science 51:4, pages 494-500.
Crossref
Crossref
Tamra Lysaght, Bernadette Richards & Anantharaman Muralidharan. (2017) Exploring the boundaries of autonomy and the ‘right’ to access innovative stem cell therapies. Asian Bioethics Review 9:1-2, pages 45-60.
Crossref
Crossref
David J. CoteNaci BalakJannick BrennumDaniel T. HolsgroveNeil KitchenHerbert KolendaWouter A. MoojenKarl SchallerPierre A. RobeTiit Mathiesen & Marike L. Broekman. (2017) Ethical difficulties in the innovative surgical treatment of patients with recurrent glioblastoma multiforme. Journal of Neurosurgery 126:6, pages 2045-2050.
Crossref
Crossref
David J. CoteAnnelien L. BredenoordTimothy R. SmithMario AmmiratiJannick BrennumIvar MendezAhmed S. AmmarNaci BalakGene BollesIgnatius Ngene EseneTiit MathiesenMarike L. Broekman. (2017) Ethical clinical translation of stem cell interventions for neurologic disease. Neurology 88:3, pages 322-328.
Crossref
Crossref
Tim K. Mackey & Virginia J. Schoenfeld. (2016) Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Medicine 14:1.
Crossref
Crossref
Kasper Raus. (2016) An analysis of common ethical justifications for compassionate use programs for experimental drugs. BMC Medical Ethics 17:1.
Crossref
Crossref
Jonathan P. Jarow, Steven Lemery, Kevin Bugin, Sean Khozin & Richard Moscicki. (2016) Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period. Therapeutic Innovation & Regulatory Science 50:6, pages 705-709.
Crossref
Crossref
Norbert Gleicher, Vitaly A. Kushnir & David H. Barad. (2016) Why Prospectively Randomized Clinical Trials Have Been Rare in Reproductive Medicine and Will Remain So?. Reproductive Sciences 23:1, pages 6-10.
Crossref
Crossref
Alison Bateman-HouseLaura KimberlyBarbara RedmanNancy DublerArthur Caplan. (2015) Right-to-Try Laws: Hope, Hype, and Unintended Consequences. Annals of Internal Medicine 163:10, pages 796-797.
Crossref
Crossref
Carolyn Neuhaus & Rachel Zacharias. (2018) Compassionate Use of Gene Therapies in Pediatrics: An Ethical Analysis. SSRN Electronic Journal.
Crossref
Crossref